86.70
-2.34 (-2.63%)
| Previous Close | 89.04 |
| Open | 89.60 |
| Volume | 1,105,405 |
| Avg. Volume (3M) | 740,154 |
| Market Cap | 5,694,481,920 |
| Price / Sales | 39.10 |
| Price / Book | 300.55 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 |
| Profit Margin | -123.28% |
| Operating Margin (TTM) | -143.73% |
| Diluted EPS (TTM) | -2.80 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 69.65% |
| Current Ratio (MRQ) | 3.30 |
| Operating Cash Flow (TTM) | -113.49 M |
| Levered Free Cash Flow (TTM) | -96.71 M |
| Return on Assets (TTM) | -51.33% |
| Return on Equity (TTM) | -150.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Rhythm Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.20 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.67% |
| % Held by Institutions | 107.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Mar 2025 | 5,604,483 |
| Nea Management Company, Llc | 31 Mar 2025 | 2,909,956 |
| Westfield Capital Management Co Lp | 31 Mar 2025 | 1,341,092 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 129.00 (Wells Fargo, 48.79%) | Buy |
| Median | 95.00 (9.57%) | |
| Low | 84.00 (JMP Securities, -3.11%) | Buy |
| Average | 101.29 (16.83%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 81.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 10 Jul 2025 | 95.00 (9.57%) | Buy | 89.04 |
| Leerink Partners | 10 Jul 2025 | 102.00 (17.65%) | Buy | 89.04 |
| 07 Jul 2025 | 88.00 (1.50%) | Buy | 66.39 | |
| Oppenheimer | 10 Jul 2025 | 110.00 (26.87%) | Buy | 89.04 |
| Wells Fargo | 10 Jul 2025 | 129.00 (48.79%) | Buy | 89.04 |
| Needham | 09 Jul 2025 | 95.00 (9.57%) | Buy | 89.00 |
| 07 May 2025 | 72.00 (-16.96%) | Buy | 64.63 | |
| JMP Securities | 26 Jun 2025 | 84.00 (-3.11%) | Buy | 61.45 |
| Stifel | 29 May 2025 | 94.00 (8.42%) | Buy | 61.88 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CRAMER PAMELA J. | - | 89.00 | -15,572 | -1,385,908 |
| GARFIELD ALASTAIR | - | 66.92 | -1,319 | -88,267 |
| GERMAN CHRISTOPHER PAUL | - | 89.00 | -3,817 | -339,713 |
| SHULMAN JOSEPH | - | 89.00 | -7,969 | -709,241 |
| SMITH HUNTER C | - | 89.00 | -42,120 | -3,748,680 |
| Aggregate Net Quantity | -70,797 | |||
| Aggregate Net Value ($) | -6,271,809 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 84.58 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CRAMER PAMELA J. | Officer | 09 Jul 2025 | Automatic sell (-) | 15,572 | 89.00 | 1,385,908 |
| CRAMER PAMELA J. | Officer | 09 Jul 2025 | Option execute | 15,572 | - | - |
| GERMAN CHRISTOPHER PAUL | Officer | 09 Jul 2025 | Automatic sell (-) | 3,817 | 89.00 | 339,713 |
| GERMAN CHRISTOPHER PAUL | Officer | 09 Jul 2025 | Option execute | 2,850 | - | - |
| SHULMAN JOSEPH | Officer | 09 Jul 2025 | Automatic sell (-) | 7,969 | 89.00 | 709,241 |
| SHULMAN JOSEPH | Officer | 09 Jul 2025 | Option execute | 7,969 | - | - |
| SMITH HUNTER C | Officer | 09 Jul 2025 | Automatic sell (-) | 42,120 | 89.00 | 3,748,680 |
| SMITH HUNTER C | Officer | 09 Jul 2025 | Option execute | 42,120 | - | - |
| SMITH HUNTER C | Officer | 07 Jul 2025 | Option execute | 6,986 | - | - |
| GARFIELD ALASTAIR | Officer | 02 Jul 2025 | Automatic sell (-) | 1,319 | 66.92 | 88,267 |
| GARFIELD ALASTAIR | Officer | 01 Jul 2025 | Option execute | 4,445 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |